Carbapenems: do they have a future?

References

1. Amyes S. G. B., Walsh F. M., Bradley J. S. 2007; Best in class: a good principle for antibiotic usage to limit resistance development?. J Antimicrob Chemother 59:825–826 [View Article][PubMed]
   [Google Scholar]
2. Brown S., Amyes S. G. B. 2006; OXA (β)-lactamases in Acinetobacter: the story so far. J Antimicrob Chemother 57:1–3 [View Article][PubMed]
   [Google Scholar]
3. Doumith M., Ellington M. J., Livermore D. M., Woodford N. 2009; Molecular mechanisms disrupting porin expression in ertapenem-resistant Klebsiella and Enterobacter spp. clinical isolates from the UK. J Antimicrob Chemother 63:659–667 [View Article][PubMed]
   [Google Scholar]
4. Edwards J. R. 1995; Meropenem: a microbiological overview. J Antimicrob Chemother 36:Suppl. A1–17[PubMed] [CrossRef]
   [Google Scholar]
5. Gehrlein M., Leying H., Cullmann W., Wendt S., Opferkuch W. 1991; Imipenem resistance in Acinetobacter baumanii is due to altered penicillin-binding proteins. Chemotherapy 37:405–412 [View Article][PubMed]
   [Google Scholar]
6. Girlich D., Poirel L., Nordmann P. 2009; CTX-M expression and selection of ertapenem resistance in Klebsiella pneumoniae and Escherichia coli . Antimicrob Agents Chemother 53:832–834 [View Article][PubMed]
   [Google Scholar]
7. Jacoby G. A., Mills D. M., Chow N. 2004; Role of β-lactamases and porins in resistance to ertapenem and other β-lactams in Klebsiella pneumoniae . Antimicrob Agents Chemother 48:3203–3206 [View Article][PubMed]
   [Google Scholar]
8. Kahan F. M., Kropp H., Sundelof J. G., Birnbaum J. 1983; Thienamycin: development of imipenen-cilastatin. J Antimicrob Chemother 12:Suppl. D1–35[PubMed] [CrossRef]
   [Google Scholar]
9. Kumarasamy K. K., Toleman M. A., Walsh T. R., Bagaria J., Butt F., Balakrishnan R., Chaudhary U., Doumith M., Giske C. G. et al. 2010; Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 10:597–602 [View Article][PubMed]
   [Google Scholar]
10. Li J., Nation R. L., Turnidge J. D., Milne R. W., Coulthard K., Rayner C. R., Paterson D. L. 2006; Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 6:589–601 [View Article][PubMed]
    [Google Scholar]
11. Livermore D. M., Sefton A. M., Scott G. M. 2003; Properties and potential of ertapenem. J Antimicrob Chemother 52:331–344 [View Article][PubMed]
    [Google Scholar]
12. Peleg A. Y., Seifert H., Paterson D. L. 2008; Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 21:538–582 [View Article][PubMed]
    [Google Scholar]
13. Poirel L., Nordmann P. 2002; Acquired carbapenem-hydrolyzing β-lactamases and their genetic support. Curr Pharm Biotechnol 3:117–127 [View Article][PubMed]
    [Google Scholar]
14. Poirel L., Nordmann P. 2006; Genetic structures at the origin of acquisition and expression of the carbapenem-hydrolyzing oxacillinase gene bla _OXA-58 in Acinetobacter baumannii . Antimicrob Agents Chemother 50:1442–1448 [View Article][PubMed]
    [Google Scholar]
15. Turton J. F., Ward M. E., Woodford N., Kaufmann M. E., Pike R., Livermore D. M., Pitt T. L. 2006; The role of ISAba1 in expression of OXA carbapenemase genes in Acinetobacter baumannii . FEMS Microbiol Lett 258:72–77 [View Article][PubMed]
    [Google Scholar]
16. Walsh T. R., Toleman M. A., Poirel L., Nordmann P. 2005; Metallo-β-lactamases: the quiet before the storm?. Clin Microbiol Rev 18:306–325 [View Article][PubMed]
    [Google Scholar]
17. Wiseman L. R., Wagstaff A. J., Brogden R. N., Bryson H. M. 1995; Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 50:73–101 [View Article][PubMed]
    [Google Scholar]